Fig. 1

Response of fibroblast HS-68 cells lines to the treatments with Anisakis products: a Dose-dependent changes in percentage of cell vitality (mean ± SD) after exposure to excretory/secretory (ES) products for 96 h in respect to control cells. ANOVA: ES 24 F _(5,30) = 2794.7, P < 0.0001; ES 48 F _(5,30) = 2969.5, P < 0.0001; ES 72 F _(5,30) = 1999.3, P < 0.0001; ES 96 F _(5,30) = 2706.6, P < 0.0001. b Dose-dependent changes in percentage of cell vitality (mean ± SD) after exposure to crude extract products (EC) for 96 h in respect to control cells. ANOVA: EC 24 F _(5,30) = 3088,8, P < 0.0001; EC 48 F _(5,30) = 3729.97, P < 0.0001; EC 72 F _(5,30) = 4109.5, P < 0.0001; EC 96 F _(5,30) = 3960.1, P < 0.0001. c Reactive oxygen species (ROS) production, expressed as relative fluorescence/ mg total proteins (means ± SD) in cell after 48 h-exposure to 0.1% concentration of Anisakis excretory/secretory (ES) and crude extract (EC) products ANOVA: F _(3,20) = 857.83, P < 0.0001. d Fold increase (means ± SD), respect to the control cells, of p53, c-fos, c-jun and GADPH mRNA expression after 48 h-exposure to 0.1% concentration of Anisakis excretory/secretory (ES) and crude extract (EC) products. ANOVA: p53 F _(2,12) = 17.4, P < 0.0001; c-fos F _(2,12) = 76.6, P < 0.0001; c-jun F _(2,12) = 54.2, P < 0.0001; GADPH F _(2,12) = 0.95, P = 0.415. Abbreviations: CO, untreated control cell lines; NAC, synthetic antioxidant N-acetilcysteine